Evidence map›Paper›PMID 27101748›Full record

ArticleEye (London, England)2016

Comment on 'Cost effectiveness of collagen crosslinking for progressive keratoconus in the UK NHS'.

D A Godefrooij, G A de Wit, M J Mangen, R P L Wisse

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

D A GodefrooijDepartment of Ophthalmology, Utrecht Cornea Research Group, University Medical Centre Utrecht, Utrecht, The Netherlands.
G A de WitJulius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands.
M J MangenJulius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands.
R P L WisseDepartment of Ophthalmology, Utrecht Cornea Research Group, University Medical Centre Utrecht, Utrecht, The Netherlands.

Funding

WASHINGTON UNIVERSITY CENTER VISION RESEARCHP30EY002687 · NEI · WASHINGTON UNIVERSITY · PI Philip Andrew Ruzycki · 1985 to 2026
$18.4M
CONTACT LENS EVALUATION IN KERATOCONUS (CLEK) STUDYU10EY010419 · NEI · UNIVERSITY OF CALIFORNIA BERKELEY · PI ZADNIK, KARLA S · 1994 to 2004
$6.4M
CLEK--DATA COORDINATING CENTERU10EY010077 · NEI · WASHINGTON UNIVERSITY · PI GORDON, MAE O · 1994 to 2004
$2.9M
CLEK STUDY CORNEAL TOPOGRAPHY READING CENTERU10EY012656 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MCMAHON, TIMOTHY T · 1999 to 2004
$2.1M
CLEK STUDY PHOTOGRAPHY READING CENTERU10EY010069 · NEI · OHIO STATE UNIVERSITY · PI BARR, JOSEPH T · 1994 to 2004
$1.9M
NEI NIH HHS P30 EY002687NEI NIH HHS U10 EY010069NEI NIH HHS U10 EY010077NEI NIH HHS U10 EY010419NEI NIH HHS U10 EY012656
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cost-Benefit AnalysisCollagenCorneal StromaCross-Linking ReagentsHumansKeratoconusPhotochemotherapyPhotosensitizing AgentsRiboflavinUltraviolet RaysVisual AcuityCollagenCross-Linking ReagentsPhotosensitizing AgentsRiboflavin

Identifiers

PMID27101748
PMCPMC4985680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.